

## Levetiracetam analogs: chemoenzymatic synthesis, absolute configuration assignment and evaluation of cholinesterase inhibitory activities

Cintia Duarte de Freitas Milagre<sup>1+\*</sup>, Bruno Sergio do Amaral<sup>1</sup>, João Marcos Batista Junior<sup>2,3</sup>, Adriana Ferreira Lopes Vilela<sup>4</sup>, Carmen Lúcia Cardoso<sup>4</sup>, Humberto Marcio Santos Milagre<sup>1</sup>

1. São Paulo State University, Institute of Chemistry, Araraquara, Brazil.
2. Federal University of São Carlos, Department of Chemistry, São Carlos, Brazil.
3. Federal University of São Paulo, Institute of Science and Technology, São José dos Campos, Brazil.
4. University of São Paulo, Faculty of Philosophy, Sciences and Letters, Ribeirão Preto, Brazil.

\*Corresponding author: Cintia Duarte de Freitas Milagre, Phone: +55 16 33019668, Email address: [cintia.milagre@unesp.br](mailto:cintia.milagre@unesp.br)

### ARTICLE INFO

Article history:

Received: July 19, 2021

Accepted: September 14, 2021

Published: April 01, 2022

### Keywords

1. *N*-heterocycles
2. *N*-alkylation
3. biocatalysis
4. electronic circular dichroism (ECD)

Section Editor: Assis Vicente Benedetti

Spectra (<sup>1</sup>H NMR, <sup>13</sup>C NMR, MS and IR) of all characterized compounds **2**, **3**, **4a–d**, **5a–b**, **5d**, **7**, **8a–d**, **9a–b** and **9d**, spectra (<sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F NMR) of the synthesized ionic liquids and the ECD figures and the lower energy conformers.




Figure S1. IR spectrum of compound **2**.




Figure S2. MS (EI, 70 eV) spectrum of compound 2.






Figure S3.  $^1\text{H}$  NMR (300.19 MHz,  $\text{CDCl}_3$ ) spectrum of compound 2.



**Figure S4.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{CDCl}_3$ ) spectrum and DEPT-135 experiment of compound **2**.



**Figure S5.** IR spectrum of compound **4a**.




Figure S6. MS (EI, 70 eV) spectrum of compound 4a.




Figure S7. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 4a.




Figure S8. <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound **4a**.




Figure S9. IR spectrum of compound **4b**.







Figure S10. MS (EI, 70 eV) spectrum of compound 4b.

Figure S11. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 4b.



**Figure S12.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{CDCl}_3$ ) spectrum and DEPT-135 experiment of compound **4b**.



**Figure S13.** IR spectrum of compound **4c**.




Figure S14. MS (EI, 70 eV) spectrum of compound **4c**.




Figure S15.  $^1\text{H}$  NMR (300.19 MHz,  $\text{CDCl}_3$ ) spectrum of compound **4c**.






Figure S16. <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound **4c**.




Figure S17. IR spectrum of compound **4d**.




Figure S18. MS (EI, 70 eV) spectrum of compound 4d.







Figure S19. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 4d.



Parameter	Value
1 Solvent	CDCl <sub>3</sub>
2 Temperature	303.0
3 Pulse Sequence	dept135
4 Number of Scans	101
5 Relaxation Delay	1.5000
6 Pulse Width	12.0000
7 Acquisition Time	1.3422
8 Spectrometer Frequency	75.48

Parameter	Value
1 Solvent	CDCl <sub>3</sub>
2 Temperature	303.2
3 Pulse Sequence	zgpg30
4 Number of Scans	307
5 Relaxation Delay	1.0000
6 Pulse Width	12.0000
7 Acquisition Time	1.3422
8 Spectrometer Frequency	75.48

**Figure S20.** <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound **4d**.



**Figure S21.** IR spectrum of compound **8a**.







Figure S22. MS (EI, 70 eV) spectrum of compound 8a.

Figure S23. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 8a.



**Figure S24.** <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound **8a**.



**Figure S25.** IR spectrum of compound **8b**.




Figure S26. MS (EI, 70 eV) spectrum of compound **8b**.






Figure S27.  $^1\text{H}$  NMR (300.19 MHz,  $\text{CDCl}_3$ ) spectrum of compound **8b**.



**Figure S28.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{CDCl}_3$ ) spectrum and DEPT-135 experiment of compound **8b**.



**Figure S29.** IR spectrum of compound **8c**.




Figure S30. MS (EI, 70 eV) spectrum of compound 8c.






Figure S31.  $^1\text{H}$  NMR (300.19 MHz,  $\text{DMSO-}d_6$ ) spectrum of compound 8c.





**Figure S32.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{DMSO-}d_6$ ) spectrum and DEPT-135 experiment of compound **8c**.



**Figure S33.** IR spectrum of compound **8d**.




Figure S34. MS (EI, 70 eV) spectrum of compound 8d.






Figure S35. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 8d.



**Figure S36.** <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound 8d.



**Figure S37.** IR spectrum of compound 5a.




Figure S38. MS (EI, 70 eV) spectrum of compound 5a.






Figure S39. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 5a.



**Figure S40.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{CDCl}_3$ ) spectrum and DEPT-135 experiment of compound **5a**.



**Figure S41.** IR spectrum of compound **5b**.







Figure S42. MS (EI, 70 eV) spectrum of compound 5b.



Figure S43. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 5b.




**Figure S44.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{CDCl}_3$ ) spectrum and DEPT-135 experiment of compound **5b**.




**Figure S45.** IR spectrum of compound **5d**.







**Figure S48.** <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound **5d**.



**Figure S49.** IR spectrum of compound **9a**.




Figure S50. MS (EI, 70 eV) spectrum of compound 9a.






Figure S51. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 9a.



**Figure S52.** <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound 9a.



**Figure S53.** IR spectrum of compound 9b.




Figure S54. MS (EI, 70 eV) spectrum of compound **9b**.




Figure S55.  $^1\text{H}$  NMR (300.19 MHz,  $\text{CDCl}_3$ ) spectrum of compound **9b**.




Figure S56. <sup>13</sup>C NMR (75.48 MHz, CDCl<sub>3</sub>) spectrum and DEPT-135 experiment of compound **9b**.




Figure S57. IR spectrum of compound **9d**.




Figure S58. MS (EI, 70 eV) spectrum of compound 9d.




Figure S59. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 9d.




Figure S60.  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{CDCl}_3$ ) spectrum and DEPT-135 experiment of compound **9d**.




Figure S61. MS (EI, 70 eV) spectrum of compound **3**.




Figure S62. MS (EI, 70 eV) spectrum of compound 7.




Figure S63. <sup>1</sup>H NMR (300.19 MHz, CDCl<sub>3</sub>) spectrum of compound 7.






Figure S64.  $^1\text{H}$  NMR (300.19 MHz,  $\text{DMSO-}d_6$ ) spectrum of compound **BMIM.BF<sub>4</sub>**.




Figure S65.  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{DMSO-}d_6$ ) spectrum and DEPT-135 experiment of compound **BMIM.BF<sub>4</sub>**.




Figure S66.  $^{19}\text{F}$  NMR (376.48 MHz,  $\text{DMSO-}d_6$ ) spectrum of compound **BMIM.BF<sub>4</sub>**.







Figure S67.  $^1\text{H}$  NMR (300.19 MHz,  $\text{DMSO-}d_6$ ) spectrum of compound **BMIM.PF<sub>6</sub>**.




**Figure S68.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{DMSO}-d_6$ ) spectrum and DEPT-135 experiment of compound **BMIM.PF<sub>6</sub>**.




**Figure S69.**  $^{19}\text{F}$  NMR (376.48 MHz,  $\text{DMSO}-d_6$ ) spectrum of compound **BMIM.PF<sub>6</sub>**.




**Figure S70.**  $^1\text{H}$  NMR (300.19 MHz,  $\text{DMSO-}d_6$ ) spectrum of compound **BMIM.NTf<sub>2</sub>**.




**Figure S71.**  $^{13}\text{C}$  NMR (75.48 MHz,  $\text{DMSO-}d_6$ ) spectrum and DEPT-135 experiment of compound **BMIM.NTf<sub>2</sub>**.




**Figure S72.**  $^{19}\text{F}$  NMR (376.48 MHz,  $\text{DMSO-}d_6$ ) spectrum of compound **BMIM.NTf<sub>2</sub>**.



**Figure S73.** (a) Experimental (black) and calculated (CAM-B3LYP/TZVP, red) ECD spectra of (*S*)-**5b**. (b) Optimized structures, relative energies and Boltzmann populations of the lowest-energy conformers identified for (*S*)-**5b** at the B3LYP/6-31G(d) level.



**Figure S74.** (a) Experimental (black) and calculated (CAM-B3LYP/TZVP, red) ECD spectra of (*S*)-9a. (b) Optimized structures, relative energies and Boltzmann populations of the lowest-energy conformers identified for (*S*)-9a at the B3LYP/6-31G(d) level.



**Figure S75.** (a) Experimental (black) and calculated (CAM-B3LYP/TZVP, red) ECD spectra of (*S*)-9b. (b) Optimized structures, relative energies and Boltzmann populations of the lowest-energy conformers identified for (*S*)-9b at the B3LYP/6-31G(d) level.